281 related articles for article (PubMed ID: 15640844)
1. Polo-like kinases (Plks) and cancer.
Takai N; Hamanaka R; Yoshimatsu J; Miyakawa I
Oncogene; 2005 Jan; 24(2):287-91. PubMed ID: 15640844
[TBL] [Abstract][Full Text] [Related]
2. Polo-like kinases and the microtubule organization center: targets for cancer therapies.
Dai W; Cogswell JP
Prog Cell Cycle Res; 2003; 5():327-34. PubMed ID: 14593727
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas.
Jang YJ; Kim YS; Kim WH
Int J Oncol; 2006 Sep; 29(3):589-94. PubMed ID: 16865274
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
Spänkuch-Schmitt B; Wolf G; Solbach C; Loibl S; Knecht R; Stegmüller M; von Minckwitz G; Kaufmann M; Strebhardt K
Oncogene; 2002 May; 21(20):3162-71. PubMed ID: 12082631
[TBL] [Abstract][Full Text] [Related]
5. Polo-like kinases and oncogenesis.
Eckerdt F; Yuan J; Strebhardt K
Oncogene; 2005 Jan; 24(2):267-76. PubMed ID: 15640842
[TBL] [Abstract][Full Text] [Related]
6. Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer.
Ahmad N
FASEB J; 2004 Jan; 18(1):5-7. PubMed ID: 14718382
[TBL] [Abstract][Full Text] [Related]
7. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
Chopra P; Sethi G; Dastidar SG; Ray A
Expert Opin Investig Drugs; 2010 Jan; 19(1):27-43. PubMed ID: 20001553
[TBL] [Abstract][Full Text] [Related]
8. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma.
Weichert W; Denkert C; Schmidt M; Gekeler V; Wolf G; Köbel M; Dietel M; Hauptmann S
Br J Cancer; 2004 Feb; 90(4):815-21. PubMed ID: 14970859
[TBL] [Abstract][Full Text] [Related]
9. Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis.
Li JJ; Li SA
Pharmacol Ther; 2006 Sep; 111(3):974-84. PubMed ID: 16603252
[TBL] [Abstract][Full Text] [Related]
10. The Plk1 target Kizuna stabilizes mitotic centrosomes to ensure spindle bipolarity.
Oshimori N; Ohsugi M; Yamamoto T
Nat Cell Biol; 2006 Oct; 8(10):1095-101. PubMed ID: 16980960
[TBL] [Abstract][Full Text] [Related]
11. Polo-box motif targets a centrosome regulator, RanGTPase.
Jang YJ; Ji JH; Ahn JH; Hoe KL; Won M; Im DS; Chae SK; Song S; Yoo HS
Biochem Biophys Res Commun; 2004 Dec; 325(1):257-64. PubMed ID: 15522227
[TBL] [Abstract][Full Text] [Related]
12. Polo-like kinases and centrosome regulation.
Dai W; Wang Q; Traganos F
Oncogene; 2002 Sep; 21(40):6195-200. PubMed ID: 12214249
[No Abstract] [Full Text] [Related]
13. Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues.
Winkles JA; Alberts GF
Oncogene; 2005 Jan; 24(2):260-6. PubMed ID: 15640841
[TBL] [Abstract][Full Text] [Related]
14. [Polo like kinase 1 expression and prognostic value in gastric carcinomas].
Lan B; Liu BY; Chen XH; Qu Y; Zhang XQ; Cai Q; Zhu ZG
Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Jan; 10(1):70-2. PubMed ID: 17253180
[TBL] [Abstract][Full Text] [Related]
15. Effect of antisense RNA targeting polo-like kinase 1 on cell cycle and proliferation in A549 cells.
Zhou Q; Bai M; Su Y
Chin Med J (Engl); 2004 Nov; 117(11):1642-9. PubMed ID: 15569479
[TBL] [Abstract][Full Text] [Related]
16. Intense nanosecond pulsed electric fields promote cancer cell apoptosis through centrosome-dependent pathway involving reduced level of PLK1.
Zou H; Gan XL; Linghu LJ; Chen C; Hu LN; Zhang Y
Eur Rev Med Pharmacol Sci; 2013 Jan; 17(2):152-60. PubMed ID: 23377802
[TBL] [Abstract][Full Text] [Related]
17. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
Bu Y; Yang Z; Li Q; Song F
Oncology; 2008; 74(3-4):198-206. PubMed ID: 18714168
[TBL] [Abstract][Full Text] [Related]
18. Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner.
Astrinidis A; Senapedis W; Henske EP
Hum Mol Genet; 2006 Jan; 15(2):287-97. PubMed ID: 16339216
[TBL] [Abstract][Full Text] [Related]
19. Getting in and out of mitosis with Polo-like kinase-1.
van Vugt MA; Medema RH
Oncogene; 2005 Apr; 24(17):2844-59. PubMed ID: 15838519
[TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
Schöffski P
Oncologist; 2009 Jun; 14(6):559-70. PubMed ID: 19474163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]